Movement Alert｜Natera Rises 3.1% in Regular Trading, Signatera Test Approved in Japan as Bladder Cancer Companion Diagnostic

Market Focus09-22

On September 22, Natera rose 3.1% in regular trading, trading at $382.10/share, with turnover of approximately $57.86 million. The move was driven by the announcement that Japan's Pharmaceuticals and Medical Devices Agency has approved the company's Signatera test as a companion diagnostic for muscle-invasive bladder cancer.

The approval supports using Signatera to guide adjuvant atezolizumab treatment decisions in patients with muscle-invasive bladder cancer. Natera expects to commercially launch the test in Japan in the first half of next year, following approval of atezolizumab for the indication. The regulatory clearance was supported by data from the late-stage IMvigor011 trial. Notably, this marks the second Japanese approval for Signatera, following its earlier clearance for colorectal cancer use in June, reinforcing Natera's expanding international footprint.

The approval builds on strong momentum, including FDA approval of Signatera CDx as a companion diagnostic in bladder cancer in May, an NCCN Category 1 recommendation in June, and EU IVDR certification in July. Multiple analyst firms maintain Buy ratings, with UBS recently raising its price target to $435.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131211984?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-22 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131211984","market":"us","top_or_hot":-1,"title":"Movement Alert｜Natera Rises 3.1% in Regular Trading, Signatera Test Approved in Japan as Bladder Cancer Companion Diagnostic","media":"Market Focus","content":"<p><p>On September 22, Natera rose 3.1% in regular trading, trading at $382.10/share, with turnover of approximately $57.86 million. The move was driven by the announcement that Japan's Pharmaceuticals and Medical Devices Agency has approved the company's Signatera test as a companion diagnostic for muscle-invasive bladder cancer.</p><p>The approval supports using Signatera to guide adjuvant atezolizumab treatment decisions in patients with muscle-invasive bladder cancer. Natera expects to commercially launch the test in Japan in the first half of next year, following approval of atezolizumab for the indication. The regulatory clearance was supported by data from the late-stage IMvigor011 trial. Notably, this marks the second Japanese approval for Signatera, following its earlier clearance for colorectal cancer use in June, reinforcing Natera's expanding international footprint.</p><p>The approval builds on strong momentum, including FDA approval of Signatera CDx as a companion diagnostic in bladder cancer in May, an NCCN Category 1 recommendation in June, and EU IVDR certification in July. Multiple analyst firms maintain Buy ratings, with UBS recently raising its price target to $435.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Natera Rises 3.1% in Regular Trading, Signatera Test Approved in Japan as Bladder Cancer Companion Diagnostic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Natera Rises 3.1% in Regular Trading, Signatera Test Approved in Japan as Bladder Cancer Companion Diagnostic\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-22 22:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 22, Natera rose 3.1% in regular trading, trading at $382.10/share, with turnover of approximately $57.86 million. The move was driven by the announcement that Japan's Pharmaceuticals and Medical Devices Agency has approved the company's Signatera test as a companion diagnostic for muscle-invasive bladder cancer.</p><p>The approval supports using Signatera to guide adjuvant atezolizumab treatment decisions in patients with muscle-invasive bladder cancer. Natera expects to commercially launch the test in Japan in the first half of next year, following approval of atezolizumab for the indication. The regulatory clearance was supported by data from the late-stage IMvigor011 trial. Notably, this marks the second Japanese approval for Signatera, following its earlier clearance for colorectal cancer use in June, reinforcing Natera's expanding international footprint.</p><p>The approval builds on strong momentum, including FDA approval of Signatera CDx as a companion diagnostic in bladder cancer in May, an NCCN Category 1 recommendation in June, and EU IVDR certification in July. Multiple analyst firms maintain Buy ratings, with UBS recently raising its price target to $435.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"","article_id":"1131211984","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131211984","pubTimestamp":1790086401,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 22, Natera rose 3.1% in regular trading, trading at $382.10/share, with turnover of approximately $57.86 million. The move was driven by the announcement that Japan's Pharmaceuticals and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc."},"translate_title":"动态警报|Natera 常规交易上涨 3.1%，Signatera 测试在日本获批作为膀胱癌伴随诊断","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1},"content_text":"On September 22, Natera rose 3.1% in regular trading, trading at $382.10/share, with turnover of approximately $57.86 million. The move was driven by the announcement that Japan's Pharmaceuticals and Medical Devices Agency has approved the company's Signatera test as a companion diagnostic for muscle-invasive bladder cancer.The approval supports using Signatera to guide adjuvant atezolizumab treatment decisions in patients with muscle-invasive bladder cancer. Natera expects to commercially launch the test in Japan in the first half of next year, following approval of atezolizumab for the indication. The regulatory clearance was supported by data from the late-stage IMvigor011 trial. Notably, this marks the second Japanese approval for Signatera, following its earlier clearance for colorectal cancer use in June, reinforcing Natera's expanding international footprint.The approval builds on strong momentum, including FDA approval of Signatera CDx as a companion diagnostic in bladder cancer in May, an NCCN Category 1 recommendation in June, and EU IVDR certification in July. Multiple analyst firms maintain Buy ratings, with UBS recently raising its price target to $435.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131211984","isCrawlerRequest":true}